Partnering

TransCode Therapeutics is actively seeking and engaging in diverse and extensive partnerships and collaborations with world-leading academic research institutes and pharmaceutical/biotechnology companies who share our vision to transform cancer treatments for patients. We seek out and evaluate collaboration opportunities that complement our innovation and business strategies. ​

Areas of Interest

• Immunotherapy - Checkpoint Inhibitors (targeting PDL1/PD-1); Pattern Recognition Receptors - targeting RIG-I gene for innate immunity
• Gene-Editing - proprietary delivery of ribonucleoproteins
• Radiotherapy - as therapies or diagnostics
• Cancer Vaccines - employing delivery of mRNA to tumors
• Diagnostics - assessing biomarkers as diagnostic aides to earlier detection, monitoring success of therapy during treatment and monitoring success post treatment
• Other targeted therapies - including peptide, protein, or small molecule-based approaches.

Partnering with TransCode

If you share our vision and passion for transforming cancer treatment, reach out. ​